NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wolfe Research

NeuroPace logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wolfe Research downgraded NeuroPace from “strong buy” to “hold.” Analyst views are mixed overall: five rate the stock Buy, five Hold, and one Sell.
  • MarketBeat reports a consensus rating of “Hold” and an average price target of $13.11. KeyCorp and Cantor Fitzgerald recently cut their targets to $14 and $12, respectively, while retaining Overweight ratings.
  • NeuroPace shares opened at $7.97 on Monday and were up 5.4%; the stock’s reported 12-month range is $5.46 to $19.60.
  • MarketBeat previews the top five stocks to own by December 1st.

NeuroPace (NASDAQ:NPCE - Get Free Report) was downgraded by research analysts at Wolfe Research from a "strong-buy" rating to a "hold" rating in a note issued to investors on Monday, Zacks reports.

Other equities analysts have also recently issued reports about the stock. Guggenheim reissued a "neutral" rating on shares of NeuroPace in a research note on Wednesday, July 29th. KeyCorp lowered their target price on shares of NeuroPace from $18.00 to $14.00 and set an "overweight" rating on the stock in a report on Friday. Cantor Fitzgerald dropped their price target on shares of NeuroPace from $21.00 to $12.00 and set an "overweight" rating on the stock in a research report on Friday. Raymond James Financial set a $21.00 price target on shares of NeuroPace in a research note on Tuesday, September 15th. Finally, Leerink Partners cut shares of NeuroPace from an "outperform" rating to a "market perform" rating and set a $7.00 price target for the company. in a research note on Friday. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $13.11.

Check Out Our Latest Stock Report on NeuroPace

NeuroPace Stock Up 5.4%

NPCE stock opened at $7.97 on Monday. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97. The business has a 50 day moving average price of $13.07 and a two-hundred day moving average price of $14.71. The company has a market cap of $273.53 million, a price-to-earnings ratio of -14.23 and a beta of 1.98. NeuroPace has a twelve month low of $5.46 and a twelve month high of $19.60.

Institutional Trading of NeuroPace

Several institutional investors and hedge funds have recently bought and sold shares of NPCE. Soleus Capital Management L.P. lifted its position in shares of NeuroPace by 10.5% in the third quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company's stock valued at $44,280,000 after buying an additional 306,878 shares during the last quarter. First Light Asset Management LLC increased its holdings in shares of NeuroPace by 16.3% during the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company's stock worth $45,464,000 after acquiring an additional 401,201 shares during the last quarter. BlackRock Inc. acquired a new position in shares of NeuroPace during the 2nd quarter worth approximately $39,369,000. Deutsche Bank AG bought a new stake in NeuroPace in the 2nd quarter valued at $14,919,000. Finally, Algert Global LLC raised its stake in NeuroPace by 2.9% in the 2nd quarter. Algert Global LLC now owns 184,774 shares of the company's stock valued at $2,936,000 after acquiring an additional 5,218 shares during the period. Institutional investors own 78.83% of the company's stock.

About NeuroPace

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

Further Reading

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in NeuroPace Right Now?

Before you consider NeuroPace, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.

While NeuroPace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines